Praliciguat
- Generic Name
- Praliciguat
- Drug Type
- Small Molecule
- Chemical Formula
- C21H14F8N6O2
- CAS Number
- 1628730-49-3
- Unique Ingredient Identifier
- R1S0H458SA
- Background
Praliciguat is under investigation in clinical trial NCT03254485 (A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (Hfpef)).
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy Volunteers
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT03499106
- Locations
- ๐บ๐ธ
IQVIA, Overland Park, Kansas, United States
A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 196
- Registration Number
- NCT03254485
- Locations
- ๐บ๐ธ
University of Arizona, Tucson, Arizona, United States
๐บ๐ธStanford University, Palo Alto, California, United States
๐บ๐ธValley Clinical Trials, Northridge, California, United States
A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
- Conditions
- Type 2 Diabetes Mellitus With Diabetic Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 156
- Registration Number
- NCT03217591
- Locations
- ๐บ๐ธ
St. Joseph Heritage Healthcare (St. Jude Hospital DBA), Fullerton, California, United States
๐บ๐ธAmerican Institute of Research, Los Angeles, California, United States
๐บ๐ธAcademic Medical Research Institute, Los Angeles, California, United States
Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension
- Conditions
- Diabetes Mellitus, Type 2Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 26
- Registration Number
- NCT03091920
- Locations
- ๐บ๐ธ
ProSciento, Inc., Chula Vista, California, United States
A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension
- Conditions
- Diabetes Mellitus, Type 2Hypertension
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 11
- Registration Number
- NCT02906579
- Locations
- ๐บ๐ธ
ICON Early Phase Unit, San Antonio, Texas, United States
Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 54
- Registration Number
- NCT02616861
- Locations
- ๐บ๐ธ
Ironwood Investigator, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.